Amiodarone-associated hemoptysis.
The manifestations of amiodarone pulmonary toxicity (APT) are generally nonspecific, and a diagnosis requires appropriate clinical history, laboratory testing consistent with toxicity, and exclusion of other disease entities. To our knowledge, hemoptysis associated with APT has not been described before; the following report describes such a case. We suggest that APT should be considered among the differential diagnosis of hemoptysis in a patient receiving amiodarone.
Vizioli
L D
LD
Department of Medicine, Albert Einstein College of Medicine, Bronx Municipal Hospital, NY.
Cho
S
S
D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects*; D006469:Hemoptysis / Q000139:chemically induced*; D006801:Humans; D008168:Lung / Q000187:drug effects; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D008297:Male
D000638:Amiodarone